SKIN6 Sep 2019 09:13
I think some are missing how much more attractive the Labskin products just became to the industry.
'The results of this study validate Labskin's ability to test multiple clinical trial and skincare products in parallel, on the cloned human skin microbiome, that is as close to the original microbiome of a human test subject, without the need for human volunteers after initial cloning takes place. This allows multiple skincare products or topical drug samples to be tested on the same subject, at the same time, thus substantially reducing development time, clinical error and clinical trial supervision costs.'
This means they can test in a more cost-effective way whilst reducing the need for human volunteers further, not only can they prove their claims but they can improve existing products faster.
Labskin and Labskin artificial intelligence combined is one of a kind groundbreaking technology, this is why they are expanding because the demand is going to be big.